Heifets BD

Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, California.

17 papers · 5 preprints · ORCID

ArticlePsychedelics

The Case for More Aggressive Masking in Psychedelic Trials.

Yang KH, Heifets BD, Krystal A +1

Europe PMC2026
ArticlePsilocybin

Serotonergic psychedelics induce distinct patterns of metabolic activity and covariance within biologically informed rat brain networks.

Gudmundsen F, Czurylo J, Rijsketic DR +10

Europe PMC2026
ArticleKetamine

Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.

Tucciarone JM, Bandeira ID, Blasey C +13

Europe PMC2026
ArticleMDMA

<i>R</i>-MDDMA is a Safer Analogue of MDMA with Therapeutic Potential.

Vargas MV, Hatzipantelis CJ, Dunlap LE +7

Europe PMC2026
ArticlePsilocybin

No evidence of immediate or persistent analgesic effect from a single dose of psilocybin in three mouse models of pain.

Gregory NS, Girard TE, Ram A +4

Europe PMC2026
PreprintPsychedelics

Serotonergic neuron-glioma interactions drive high-grade glioma pathophysiology

Drexler R, Yalçın B, Mancusi R +15

Europe PMC2025
ArticleMDMA

History, pharmacology and therapeutic mechanisms of 3,4-methylenedioxymethamphetamine (MDMA).

Casey AB, Heifets BD

Europe PMC2026
PreprintPsychedelics

Treatment Expectation is the Strongest Predictor of Willingness to Participate in Psychedelic Clinical Trials

Payton AP, Flohr JR, Heifets BD +1

Europe PMC2025
ArticleKetamine

Methodological considerations for interpreting ketamine-naltrexone trials in depression.

Bandeira ID, Jelen LA, Tucciarone JM +3

Europe PMC2025
ArticlePsychedelics

The psychoplastogen tabernanthalog induces neuroplasticity without proximate immediate early gene activation.

Aarrestad IK, Cameron LP, Fenton EM +35

Europe PMC2025
ArticleMDMA

5-HT<sub>2C</sub> receptors in the nucleus accumbens constrain the rewarding effects of MDMA.

Pomrenze MB, Vaillancourt S, Salgado JS +12

Europe PMC2025
PreprintPsilocybin

Psilocybin has no immediate or persistent analgesic effect in acute and chronic mouse pain models

Gregory NS, Girard TE, Ram A +4

Europe PMC2025
PreprintPsychedelics

The Psychedelic Media Exposure Questionnaire: The development and validation of a new scale assessing psychedelic-related media exposure

Evers A, Kelly C, Noorani T +2

Europe PMC2025
PreprintPsilocybin

A multi-institutional investigation of psilocybin’s effects on mouse behavior

Lu OD, White K, Raymond K +19

Europe PMC2025
ArticleKetamine

Opioids diminish the placebo antidepressant response: Observational post hoc findings from a randomized controlled ketamine trial.

Lii TR, Flohr JR, Okada RL +4

Europe PMC2025
ArticleMDMA

Negative Affect Circuit Subtypes and Neural, Behavioral, and Affective Responses to MDMA: A Randomized Clinical Trial.

Zhang X, Hack LM, Bertrand C +11

Europe PMC2025
ArticleKetamine

Maintenance Intramuscular Ketamine-Assisted Psychotherapy, a Retrospective Chart Review of Efficacy, Adverse Events, and Dropouts from a Community Practice.

Ryan WC, Heifets BD

Europe PMC2025
ArticlePsilocybin

Expectancy Effects in Psychedelic Trials.

Szigeti B, Heifets BD

Europe PMC2024
ArticlePsychedelics

Therapeutic mechanisms of psychedelics and entactogens.

Heifets BD, Olson DE

Europe PMC2024
ArticlePsilocybin

UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice.

Rijsketic DR, Casey AB, Barbosa DAN +8

Europe PMC2023
ArticlePsychedelics

Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials.

Aday JS, Heifets BD, Pratscher SD +3

Europe PMC2022
ArticlePsilocybin

Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.

De Gregorio D, Aguilar-Valles A, Preller KH +4

Europe PMC2021